The artificial peptide PABL resembles the previously published cell-permeable biosensor peptide used to monitor the BCR-ABL1 function in CML (Yang et al., 2013), with “reporter” and “target” sequences in common. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.